Laddar populära aktier...
Redeye updates on EG7 post Q3-results which were better than expected, driven by strong profitabilit...
Q3 in line with promising outlook for 2025 Large revisions as Kaktus divestment moving from '24e to ...
Trots att försäljning och resultat kom in under våra förväntningar i kvartalet kvarstår vår positiva...
Redeye states the report was 2% higher in sales while higher OPEX weighted on the EBITDA and EBIT re...
Redeye gives a short comment on yesterday’s news that Curasight has announced brain cancer as the fi...
Redeye sees a solid Q3 report with an improved cash burn, and we welcome the increased gross margin ...
Redeye provides an updated view on Genovis following a Q3 report that surpassed our estimates across...
In its CMD, Vaisala outlined its strategy and updated long-term financial targets.
Redeye reiterates its valuation following the Q3 2024 report, which showed slight positive deviation...
Net sales and EBITDA were close to our expectations in Q3 but slightly below LSEG Data & Analytics c...
Nettoomsättningen för det tredje kvartalet uppgick till 113,8 MSEK (97,5), vilket motsvarade en orga...
FX/Other hampered the results, underlying in line Crypto rallying, we raise adj.
Obducat har publicerat bolagets Q3-rapport, vilken visade på en stark exekvering under kvartalet med...
Europe recovered and FY guidance kept EBITA cut 2-4%, eyes starting to shift to 2025e Higher organic...
Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and recent events...
